Slide 1: SGX General Announcement: Result Briefing FY2025
Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED GENERAL ANNOUNCEMENT::RESULT BRIEFING FY2025 Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announcement Title General Announcement Date &Time of Broadcast 27-Feb-2026 17:47
Slide 2: Results Briefing FY2025
RESULTS BRIEFING FY2025 2 Mar 2026 HYPHENS PHARMA INTERNATIONAL LIMITED
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: Agenda
Agenda 01 Business Updates 02 Financial Results 03 Business Outlook
Slide 5: Business Updates
oe g% Hyphens - a Business Updates
Slide 6: Business updates
Business updates Extended our Metoject® agreement with Launch novel medac GmbH to acne treatment include Thailand Winlevi®, to and Cambodia. Singapore and Licensed DermaQuick® Malaysia Introduced NCTF 135 HA® VZV across Southeast and Artfiller® to Malaysia Asia in partnership with Maruho Co., Ltd. J
Slide 7: Financial Results
g% Hyphens Financial Results
Slide 8: Product Portfolio Optimization Has Borne Fruits
Product Portfolio Optimization Has Borne Fruits Revenue Gross Profit (SGD'm) and Gross Profit Margin(%) (SGD'm) 80.0 43.0% 250.0 69.5 72.2 42.0% 70.0 62.8 61.9 195.4 40.7% 41.0% 60.0 200.0 170.6 177.4 40.0% 162.3 48.1 50.0 43.6 38.7% 39.0% 150.0 40.0 38.0% 121.0 125.9 30.0 38.2% 37.0% 100.0 36.0% 20
Slide 9: Earnings Doubled in Second Half of 2025
Earnings Doubled in Second Half of 2025 Profit After Tax (SGD'm) 5.9 5.1 5.0 4.1 3.5 2.0 1H2023 2H2023 1H2024 2H2024 1H2025 2H2025
Slide 10: Strong Operating Cashflow Continued In 2H2025
Strong Operating Cashflow Continued In 2H2025 Operating cashflow (SGD'm) The business continued to release working capital from the inventory in 11.48 2H2025. Full year net operating cash inflow of S$18.7m. 7.27 0.48 (0.42) 1H2024 2H2024 1H2025 2H2025
Slide 11: Performance by Geography
Performance by Geography Revenue by Geography Others*, SGDm 10% +2.5%, 93.2 Malaysia, Singapore 15% 90.9 Singapore, 53% 2025 -30.8%, 39.5 Vietnam, Vietnam 22% 57.1 +6.2%, 27.4 Malaysia Others*, 25.8 11% -20.2%, 17.3 Singapore, Malaysia, Others* 21.6 47% 13% 2024 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.
Slide 12: Revenue by Segment
Revenue by Segment Revenue by Segments (SGDm) • Pharmaceutical and Medical 120.0 Aesthetics revenue decreased in 2H2025 vs. 1H2025 due to 99.7 • Transition of Visiopro® and 100.0 95.9 95.8 Fenosup® to Proprietary 89.5 87.8 Brands; 21.7 21.9 22.0 • Discontinuation of export of 80.0 74.7 20.4 19.0 Phy
Slide 13: Segment Profitability
Segment Profitability EBITDA by Segment • Pharmaceutical and Medical Aesthetics: (SGDm) • EBITDA in 2H2025 doubled to S$7.8m compared to 1H2025 benefiting from lower inventory provision and forex losses • Proprietary Brands • Reduced by S$1.5m to S$1.1m in 8.5 2H2025 compared to 1H2025. This is beca
Slide 14: Business Outlook
Business Outlook
Slide 15: Business Outlook
Business Outlook Pharmaceutical and Digital Platform and Proprietary Brands Medical Aesthetics E-Pharmacy Winlevi® expects further country Product portfolio optimization has Digital Platform and e-Pharmacy launches in 2026, with potential borne fruits with improved GPM continues to scale with the la
Slide 16: Q&A
Q&A
Slide 17: Let's improve lives together.
Let’s improve lives together. Hyphens Pharma International Limited (SGX: 1J5) hyphens-pharma-international https://www.hyphensgroup.com/ 16 Tai Seng Street, Level 4, Singapore 534138